US likely to get second COVID vaccine Moderna showing high efficacy
New Delhi: The US is likely to get its second COVID-19 vaccine soon in the form of Moderna’s candidate. The country is currently receiving first few doses of Pfizer-BioNTech.
The coronavirus vaccine has been approved for emergency use on Saturday. Recent reports suggest that Moderna’s COVID-19 vaccine has shown high efficacy against COVID-19 and was found to be highly productive.
Reports further suggest that the vaccine could receive emergency use authorization from the US Food and Drug Administration, soon.
The FDA has reportedly also confirmed that Moderna’s COVID-19 vaccine is 94.1 per cent effective against COVID-19, a claim that the pharma company had made earlier based on trials of 30,000 people. The efficacy was recorded at 86.4 per cent for people who were 65 years or older.
The agency has further said that common side effects of vaccination, such as fatigue, fever, headache, etc were experienced by trials participants. While they were called ‘unpleasant’, they were not dangerous. One trial participant experienced Bell’s Palsy, a facial paralysis condition.
The report further said that Moderna’s COVID-19 vaccine will work equally well in white people, and people of colour. No significant difference was noted in the immune response produced in men and women as well, or even in healthy people and those with existing conditions such as diabetes or obesity.